Dr Selvambigai Manivannan

Dr Selvambigai Manivannan

Institute of Metabolism and Systems Research
Postdoctoral Research Fellow

Selvambigai Manivannan is a Postdoctoral Research Fellow working with Associate Professor Vicki Smith in the Institute of Metabolism and Systems Research. Her current research interests include elucidating the dysregulated signaling pathways and downstream targets implicated in promoting thyroid cancer metastasis and invasion. In particular, by using advanced microscopy, proteomics and cell biological techniques, Selvambigai is investigating the precise role of proto-oncogene signaling [e.g. PTTG1-Binding Factor (PBF)] in thyroid cancer cell motility. This work aims to identify novel therapeutic targets and approaches for improving thyroid cancer treatment.

Qualifications

  • Associate Fellow of Higher Education Academy (AFHEA), 2018
  • PhD (Molecular Cell Biology) University of Groningen, Netherlands, 2014
  • MSc (University Rank Holder with Honours in Life Sciences), Bharathidasan University, Trichy, India, 2009

Teaching

  • Medicine and Surgery MBChB Year 2 - Understanding Thyroid Function
  • MRes - Cancer Metastasis and Invasion
  • Pharmacy MPharm - Understanding Thyroid Function
  • Medicine and Surgery MBChB Year 1 - Research Taster
  • Biomedical Science BSc & MSc - Research Supervision

Other activities

Current member of the following societies

  • American Thyroid Association (ATA)
  • The British Endocrine Society (BES)
  • British Society of Cell Biology (BSCB)
  • European Association for Cancer research (EACR)
  • British Association of Cancer Biology (BACR)
  • British Mass Spectrometry Society (BMSS)
  • Editorial Board Member for Journal of Biomolecular Concepts.
  • Editorial Board Member for International Journal of Biotechnology and Biomaterials Engineering.

Publications

Recent publications

Article

Read, M, Brookes, K, Zha, L, Manivannan, S, Kim, J, Kocbiyik, M, Fletcher, A, Gorvin, CM, Firth, G, Fruhwirth, G, Nicola, J, Jhiang, S, Ringel, M, Campbell, M, Sunassee, K, Blower, P, Boelaert, K, Nieto, H, Smith, V & McCabe, C 2023, 'Combined Vorinostat and Chloroquine Inhibit Sodium Iodide Symporter Endocytosis and Enhance Radionuclide Uptake In Vivo', Clinical Cancer Research. https://doi.org/10.1158/1078-0432.CCR-23-2043

Abstract

Brookes, K, Zha, L, Small, B, Kim, J, Manivannan, S, Thornton, C, Kannappan, V, Wang, W, Nieto, H, Sunassee, K, Blower, P, Smith, V, Read, M & McCabe, C 2023, 'A copper-based metabolite of disulfiram upregulates sodium iodide symporter (NIS) gene expression to enhance thyroidal uptake of radionuclides in vivo', Endocrine Abstracts, vol. 94, OC7.1. https://doi.org/10.1530/endoabs.94.OC7.1

Manivannan, S, Banga, D, Kocbiyik, M, Read, M, Zha, L, Brookes, K, Nieto, H, McCabe, C & Smith, V 2023, 'A critical role for the proto-oncogene PBF in regulating cellular adhesion and motility in thyroid cancer', Endocrine Abstracts, vol. 94, OC2.6. https://doi.org/10.1530/endoabs.94.OC2.6

Brookes, K, Zha, L, Kim, J, Small, B, Kocbiyik, M, Manivannan, S, Kannappan, V, Wang, W, Sunassee, K, Blower, P, Nieto, H, Smith, V, Read, M & McCabe, C 2023, 'Copper-based therapeutics increase sodium/iodide symporter (NIS) transcription and enhance radioiodide uptake in thyroid cancer cells', Endocrine Abstracts, vol. 90, OC11.1. https://doi.org/10.1530/endoabs.90.OC11.1

Manivannan, S, Kocbiyik, M, Alshahrani, M, El-Asrag, ME, Zha, L, Brookes, K, Nieto, H, Read, M, Beggs, A, McCabe, C & Smith, V 2023, 'Elucidating the mechanisms via which the proto-oncogene PBF stimulates cell motility in thyroid tumour progression', Thyroid Research, vol. 16, no. S1, PO2, pp. 6-6. https://doi.org/10.1186/s13044-023-00170-8

Manivannan, S, Kocbiyik, M, Alshahrani, M, EI-Asrag, M, Zha, L, Brookes, K, Nieto, H, Read, M, Beggs, A, McCabe, C & Smith, V 2023, 'Elucidating the mechanisms via which the proto-oncogene Pbf stimulates cell motility in thyroid tumor progression', Thyroid, vol. 33, no. S1, Poster 338, pp. A62-A62. https://doi.org/10.1089/thy.2023.29156.abstracts

Brookes, K, Zha, L, Kim, J, Kocbiyik, M, Manivannan, S, Sunassee, K, Blower, P, Nieto, H, Smith, V, Read, M & McCabe, C 2023, 'Exploiting endocytic factors as druggable targets to enhance sodium iodide symporter activity with clinical implications for radioiodide therapy', Thyroid Research, vol. 16, no. Supplement 1, OR4, pp. 4-4. https://doi.org/10.1186/s13044-023-00170-8

Brookes, K, Zha, L, Kim, J, Kocbiyik, M, Manivannan, S, Sunassee, K, Blower, P, Nieto, H, Smith, V, Read, M & McCabe, C 2023, 'Exploiting endocytic factors as druggable targets to enhance sodium iodide symporter activity with clinical implications for radioiodide therapy', Thyroid, vol. 33, no. S1, Poster 273, pp. A33-A34. https://doi.org/10.1089/thy.2023.29156.abstracts

Read, M, Brookes, K, Zha, L, Manivannan, S, Kim, J, Firth, G, Sunassee, K, Blower, P, Boelaert, K, Nieto, H, Smith, V & McCabe, C 2023, 'Manipulating NIS endocytosis as a druggable target to enhance radioiodide uptake and prognostic indictor of thyroid cancer recurrence', Endocrine Abstracts, vol. 94, OC2.1. https://doi.org/10.1530/endoabs.94.OC2.1

Zha, L, Brookes, K, Kim, J, Small, B, Kocbiyik, M, Manivannan, S, Nieto, H, Bottegoni, G, Cox, L, Kannappan, V, Wang, W, Sunassee, K, Blower, P, Smith, V, Read, M & McCabe, C 2023, 'Rational drug design of VCP inhibitors to enhance NIS function in radioiodide therapy', Thyroid Research, vol. 16, no. S1, OR3, pp. 4-4. https://doi.org/10.1186/s13044-023-00170-8

Read, M, Zha, L, Brookes, K, Kim, J, Small, B, Kocbiyik, M, Manivannan, S, Bottegoni, G, Cox, L, Kannappan, V, Wang, W, Sunassee, K, Blower, P, Nieto, H, Smith, V & McCabe, C 2023, 'Rational drug design of VCP inhibitors to enhance nis function in radioiodide therapy', Thyroid, vol. 33, no. S1, Oral 8, pp. A4-A4. https://doi.org/10.1089/thy.2023.29156.abstracts

Manivannan, S, Alshahrani, M, Thornton, C, Raja, S, Kocbiyik, M, Zha, L, Brookes, K, Nieto, H, Read, M, McCabe, C & Smith, V 2022, 'Promotion of thyroid cancer cell migration and invasion by the proto-oncogene PBF is mediated by FGD1 and N-WASP', Thyroid, vol. 32, no. S1, OC27, pp. A91-A91. https://doi.org/10.1089/thy.2022.29137.abstracts

Read, M, Brookes, K, Zha, L, Moolla, M, Kocbiyik, M, Manivannan, S, Hoare, R, Kannappan, V, Wang, W, Sunassee, K, Blower, P, Nieto, H, Smith, V & McCabe, C 2022, 'Repurposing disulfiram as a therapeutic agent to enhance sodium iodide symporter activity in radioiodide therapy', Endocrine Abstracts, vol. 86, OC2.6. https://doi.org/10.1530/endoabs.86.OC2.6

Brookes, K, Zha, L, Moolla, M, Kim, J, Kocbiyik, M, Manivannan, S, Nieto, H, Kannappan, V, Wang, W, Sunassee, K, Blower, P, Smith, V, Read, M & McCabe, C 2022, 'Repurposing of disulfiram and diethyldithiocarbamate (DDC)-metal complexes to enhance sodium iodide symporter function in radioiodide therapy', Thyroid, vol. 32, no. S1, OC40, pp. A96-A97. https://doi.org/10.1089/thy.2022.29137.abstracts

Preprint

Read, M, Brookes, K, Zha, L, Manivannan, S, Kim, J, Kocbiyik, M, Fletcher, A, Gorvin, CM, Firth, G, Fruhwirth, G, Nicola, J, Jhiang, S, Ringel, M, Campbell, M, Sunassee, K, Blower, P, Boelaert, K, Nieto, H, Smith, V & McCabe, C 2023 'Dissecting endocytic mechanisms reveals new molecular targets to enhance sodium iodide symporter activity with clinical relevance to radioiodide therapy' bioRxiv. https://doi.org/10.1101/2023.05.22.541733

View all publications in research portal